Pig-mouse chimeric antibody for resisting porcine delta coronavirus and application of pig-mouse chimeric antibody
A pig-mouse chimeric antibody effectively neutralizes PDCoV, addressing the lack of effective antibodies by using specific chains expressed in mammalian cells and purified in a recombinant vector, enhancing antiviral efficacy and safety.
Patent Information
- Application Number
- CN202411236682.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-04
AI Technical Summary
There is a lack of effective and safe chimeric antibodies against porcine delta coronavirus (PDCoV) for vaccine development and antiviral drugs, leading to significant threats to the pig industry due to rapid virus spread causing severe diarrhea and dehydration in newborn piglets.
Development of a pig-mouse chimeric antibody composed of specific heavy and light chains, expressed using a recombinant vector in mammalian cells, and purified using a Protein A column, which reduces immune side effects and enhances antiviral efficacy.
The chimeric antibody effectively neutralizes PDCoV, showing strong antiviral therapeutic effects and reducing immune reactions, providing a practical solution for preventing and treating PDCoV infections.
Smart Images

Figure CN119080921A_ABST
Abstract
Description
Technical Field
[0001] The present invention specifically relates to a pig-mouse chimeric antibody against porcine delta coronavirus and its application. Background Art
[0002] Porcine deltacoronavirus (PDCoV) is a newly discovered porcine enteric coronavirus belonging to the genus deltacoronavirus. The virus is a non-segmented single-stranded positive-strand RNA virus with a genome length of approximately 25.4kb, including a 5′ non-coding region and a 3′ non-coding region, encoding four major structural proteins: surface spike protein (S), small membrane protein (E), membrane protein (M) and nucleocapsid (N) protein. The virus mainly infects the small intestine of pigs, especially the jejunum and ileum, causing atrophy of the villus epithelial cells of the small intestine and causing severe atrophic enteritis. The clinical symptoms are mainly watery diarrhea, vomiting and dehydration death in newborn piglets. In recent years, PDCoV has spread rapidly in my country, seriously threatening the healthy development of the pig industry.
[0003] Monoclonal antibodies are highly specific and affinity antibodies produced by a single cell. Since their introduction, they have been rapidly applied to many fields of modern medicine due to their unique advantages, such as the detection of pathogenic microorganism antigens and antibodies in the development of medical diagnostic reagents, the detection of tumor markers, the detection and identification of immune cells and their subsets, and the determination of hormones and cytokines. At present, chimeric antibody technology, reconstructed antibody technology and surface remodeling technology have been developed to overcome the immune side effects induced by the recognition of the mouse part of the antibody by the heterologous immune system. However, there is no research on chimeric antibodies against porcine delta coronavirus to obtain safe and efficient vaccines or antiviral drugs. Summary of the invention
[0004] To solve the above problems, the present invention provides a pig-mouse chimeric antibody against porcine delta coronavirus, which is composed of a heavy chain and a light chain; the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.3, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.5, the amino acid sequence of the light chain constant region is shown in SEQ ID NO.4, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.6.
[0005] The present invention also provides a gene fragment encoding the aforementioned pig-mouse chimeric antibody, which comprises a gene fragment encoding a heavy chain as shown in SEQ ID NO.1, and a gene fragment encoding a light chain as shown in SEQ ID NO.2.
[0006] The present invention also provides a recombinant vector for expressing the aforementioned pig-mouse chimeric antibody, which is an expression vector in which a gene fragment encoding a heavy chain as shown in SEQ ID NO.1 is inserted into the XbaⅠ and NotⅠ restriction sites, and a gene fragment encoding a light chain as shown in SEQ ID NO.2 is inserted into the HindⅢ and EcoRⅠ restriction sites;
[0007] The expression vector includes a PKS001 plasmid vector.
[0008] The present invention also provides a recombinant cell expressing the aforementioned pig-mouse chimeric antibody, which is a mammalian cell comprising the aforementioned recombinant vector, preferably ExpiCHO-S or CHO-K1 cell.
[0009] The present invention also provides a method for preparing the aforementioned pig-mouse chimeric antibody, comprising the following steps: taking the aforementioned recombinant vector, transfecting cells, culturing, and purifying the supernatant; the transfection includes transient transfection and stable transfection.
[0010] Furthermore, the transient transfection method is as follows: OptiPRO SFM and the recombinant vector are mixed in tube A; OptiPRO SFM and ExpiFectamineCHO Reagent are mixed in tube B; the solutions in tubes A and B are mixed and allowed to stand for 5 minutes, then added to the cell culture medium, and after culturing for 20 hours, ExpiCHO Feed and ExpiCHO Enhancer are added, and culture is continued until the 5th day, and ExpiCHO Feed is added and cultured until the cell viability drops below 70%.
[0011] Furthermore, the ratio of OptiPRO SFM to recombinant vector in tube A is 2 ml:40 μg;
[0012] The ratio of OptiPRO SFM and ExpiFectamineCHO Reagent in tube B is 1.84 ml:160 μl;
[0013] The ratio of the cell culture medium to the recombinant vector is 50 ml: 40 μg;
[0014] The volume ratio of the cell culture medium to the ExpiCHO Feed and ExpiCHO Enhancer added after 20 hours of culture and the ExpiCHO Feed added on the 5th day of culture is 50 ml: 8 ml: 300 μl: 8 ml;
[0015] The cells in the cell culture solution are ExpiCHO-S cells, and the culture medium is ExpiCHO Expression Medium;
[0016] The culture conditions are: rotation speed 95 rpm, temperature 37° C., CO 2 concentration 8%.
[0017] Furthermore, the purification is to purify the supernatant using a Protein A recombinant protein purification prepacked column.
[0018] The present invention also provides a use of the aforementioned pig-mouse chimeric antibody in the preparation of a drug for preventing and / or treating porcine delta coronavirus infection.
[0019] Finally, the present invention provides a vaccine for preventing porcine delta coronavirus, which is prepared by using the aforementioned porcine-mouse chimeric antibody as an antigen and adding a pharmaceutically acceptable carrier.
[0020] The present invention utilizes a neutralizing mouse monoclonal antibody 1H10 prepared in the early stage that specifically recognizes the S protein of PDCoV, performs genetic engineering recombination transformation, constructs a recombinant expression vector expressing a pig-mouse chimeric genetic engineering antibody, and expresses the pig-mouse chimeric antibody ch1H10 in CHO cells. Cell experiments prove that the ch1H10 antibody can specifically recognize PDCoV, has good virus binding activity and neutralization activity, and in vivo experiments show that the chimeric antibody has a strong antiviral therapeutic effect on PDCoV-infected piglets. Since the recombinant pig-mouse chimeric antibody ch1H10 contains only a mouse variable region sequence, which is responsible for specific antigen recognition, and the pig FC fragment is homologous to the PDCoV host (pig), the heterologous reaction of the antibody in the pig can be effectively reduced, and the immune side effects produced are avoided to shorten the half-life of the antibody, reduce the actual efficacy and may cause serious adverse reactions, and enhance the neutralization therapeutic effect of the antibody, providing a practical genetic engineering antibody for the prevention and treatment of PDCoV, which has important clinical application value.
[0021] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0022] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Schematic diagram of antibody recombination;
[0024] Figure 2 Schematic diagram of the construction and expression process of stable vectors;
[0025] Figure 3Schematic diagram of the in vivo treatment experiment flow in piglets
[0026] Figure 4 Schematic diagram of ch1H10 transient transfection vector
[0027] Figure 5 Antibody heavy chain and light chain amplified electrophoresis bands (A: Antibody heavy chain amplified electrophoresis band; B: Antibody light chain amplified electrophoresis band)
[0028] Figure 6 Schematic diagram of antibody stable transfection plasmid
[0029] Figure 7 Ch1H10 purification peak
[0030] Figure 8 SDS-PAGE verification of ch1H10 (A: verification diagram of antibody purification effect; B: reduction / non-reduction verification diagram of purified antibody ch1H10)
[0031] Fig. 9 Results of ch1H10 cytotoxicity assay
[0032] Fig.10 ch1H10 EC50 experimental results
[0033] Fig.11 ELISA results
[0034] Fig.12 IFA experimental results (magnification 40x)
[0035] Fig.13 IFA experimental results (magnification 100x)
[0036] Fig.14 Piglet diarrhea score
[0037] Fig.15 Figure 1: The situation around the anus of piglets in the blank control group
[0038] Fig.16 The picture of the anus surrounding the piglets in the treatment groups (A: The picture of the anus surrounding the piglets in the treatment group ZL-1; B: The picture of the anus surrounding the piglets in the treatment group ZL-2; C: The picture of the anus surrounding the piglets in the treatment group ZL-3; D: The picture of the anus surrounding the piglets in the treatment group ZL-4; E: The picture of the anus surrounding the piglets in the treatment group ZL-5)
[0039] Fig.17 Figure 3: The situation around the anus of piglets in the challenge group (A: The situation around the anus of piglets GD-1 in the challenge group; B: The situation around the anus of piglets GD-2 in the challenge group; C: The situation around the anus of piglets GD-3 in the challenge group; D: The situation around the anus of piglets GD-4 in the challenge group; E: The situation around the anus of piglets GD-5 in the challenge group;)
[0040] Fig.18 Autopsy of piglets in the blank control group (A: Autopsy of piglets in the blank control group MOCK-1; B: Autopsy of piglets in the blank control group MOCK-2; C: Autopsy of piglets in the blank control group MOCK-3;)
[0041] Fig.19 Autopsy of piglets in the challenge group (A: Autopsy of piglets GD-1 in the challenge group; B: Autopsy of piglets GD-2 in the challenge group; C: Autopsy of piglets GD-3 in the challenge group; D: Autopsy of piglets GD-4 in the challenge group; E: Autopsy of piglets GD-5 in the challenge group;)
[0042] Fig. 20 Autopsy of piglets in the treatment groups (A: Autopsy of piglets in the treatment group ZL-1; B: Autopsy of piglets in the treatment group ZL-2; C: Autopsy of piglets in the treatment group ZL-3; D: Autopsy of piglets in the treatment group ZL-4; E: Autopsy of piglets in the treatment group ZL-5;)
[0043] Fig.21 The number of virus copies in the intestinal tissues of piglets (A: PDCoV virus copy number in the duodenum tissue; B: PDCoV virus copy number in the jejunum tissue; C: PDCoV virus copy number in the ileum tissue; D: PDCoV virus copy number in the cecum tissue; E: PDCoV virus copy number in the colon tissue; F: PDCoV virus copy number in the rectum tissue;)
[0044] Fig. 22 The number of virus copies excreted from anal swabs of piglets (A: the number of virus copies excreted from anal swabs of piglets in the treatment group every day; B: the number of virus copies excreted from anal swabs of piglets in the challenge group every day;)
[0045] Fig.23 HE staining of intestinal tissues in the treatment groups (magnifications were 20x and 40x, respectively) (A: HE staining of the jejunum and ileum of piglet ZL-1 in the treatment group; B: HE staining of the jejunum and ileum of piglet ZL-2 in the treatment group; C: HE staining of the jejunum and ileum of piglet ZL-3 in the treatment group; D: HE staining of the jejunum and ileum of piglet ZL-4 in the treatment group; E: HE staining of the jejunum and ileum of piglet ZL-5 in the treatment group;)
[0046] Fig.24HE staining of intestinal tissues in the challenge group (magnifications were 20x and 40x, respectively) (A: HE staining of the jejunum and ileum of piglet GD-1 in the challenge group; B: HE staining of the jejunum and ileum of piglet GD-2 in the challenge group; C: HE staining of the jejunum and ileum of piglet GD-3 in the challenge group; D: HE staining of the jejunum and ileum of piglet GD-4 in the challenge group; E: HE staining of the jejunum and ileum of piglet GD-5 in the challenge group;)
[0047] Fig.25 HE staining of intestinal tissues in the blank control group (magnifications were 20x and 40x, respectively) (A: HE staining of the jejunum and ileum of piglet MOCK-1 in the blank group; B: HE staining of the jejunum and ileum of piglet MOCK-2 in the blank group.)
[0048] Fig.26 Immunohistochemistry of intestinal tissues in the challenge group (magnifications were 20x and 40x respectively)
[0049] Fig. 27 Immunohistochemistry of intestinal tissue in the treatment group (magnifications are 20x and 40x respectively)
[0050] Fig.28 Immunohistochemistry of intestinal tissue in the blank control group (magnifications are 20x and 40x respectively) DETAILED DESCRIPTION
[0051] Example 1 Preparation and application of genetically engineered chimeric antibodies against porcine delta coronavirus (PDCoV)
[0052] 1. Materials and methods
[0053] 1.1 Experimental Materials
[0054] 1.1.1 Cells, plasmids and strains
[0055] ExpiCHO-S cells, pks001 eukaryotic vector, CHO-K1 cells, and PDCoV isolate CHN-SC2015 (GeneBank accession number: KY398010) were preserved by the Swine Disease Research Center of Sichuan Agricultural University; TOP10 competent cells were purchased from Angyu Biotechnology; a hybridoma cell expressing anti-PDCoV S protein neutralizing monoclonal antibody 1H10 was prepared and preserved in the early stage by the Swine Disease Research Center.
[0056] 1.1.2 Kits and main biochemical reagents
[0057] Max DNA polymerase, PrimeScript RT reagent Kit, Xba I, Not I, EcoRⅠ, and HindⅢ were purchased from Dalian Bao Bioengineering Co., Ltd.; HRP-Goat anti Pig IgG was purchased from Solebao; FITC-Goat anti Pig IgG and HighGene transfection reagent were purchased from Abotek Biotechnology Co., Ltd.; 555-donkey anti-mouse IgG was purchased from BioSky; HiScript IIQ RT SuperMix for qPCR (+gDNA wiper) and ChamQ Universal SYBR qPCR Master Mix were purchased from Novozymes Biotech Co., Ltd.; CHO cell culture medium CHO CD04 Medium was purchased from Zhongshan Kangtian Shenghe Biotechnology Co., Ltd.; Cellvento 4CHO-C Cloning Medium was purchased from Sigma-Aldrich; Cell Boost7a and Cell Boost7b were purchased from Hyclone; Cck-8 reagent was purchased from Taoshu Biotechnology; and SteadyPure RNA extraction kit was purchased from Aikerui Biotechnology Co., Ltd.
[0058] 1.1.3 Experimental animals
[0059] Five-day-old suckling piglets were provided by Chenghua Pig Protection Research Base (Chengdu). All piglets were free of PDCoV, CSFV, PCV2, PRRSV, TGEV, and PEDV pathogens after laboratory PCR testing. The animal experiment protocol was reviewed by the Experimental Animal Ethics and Welfare Committee of Sichuan Agricultural University and strictly followed the Animal Experimental Operation Procedure of Sichuan Agricultural University [Permit No. SYSK (Chuan 2019-187)].
[0060] 1.1.4 Main equipment
[0061] Low-temperature desktop high-speed centrifuge (CF1524R, Scilogex, USA); PCR instrument, microplate reader (Bio-Rad, USA); CO2-resistant horizontal shaker (Seiki Co., Ltd., USA); biosafety class II operation cabinet (Forma class II, A2Biological Satety Cabinet Thereto electron corporation); 125ml cell shake flask and 500ml cell shake flask, both purchased from Nunc; upright fluorescence microscope (BX53, OLYMPUS, Japan), cell counter (IE1000, Ruiyu Biotechnology Co., Ltd.).
[0062] 1.2 Methods
[0063] 1.2.1 Codon optimization and transient vector synthesis
[0064] The variable region sequence of the neutralizing monoclonal antibody 1H10 prepared in the laboratory and specific for the PDCoV S1 protein was determined. The variable region sequence was divided into VL and VH, and the variable region sequence was obtained from the National Center for Biotechnology Information (NCBI). https: / / www.ncbi.nlm.nih.gov / nuccore / ab699686 ) and the International Immunogenetics Database IMGT (https: / / www.imgt.org / ligmdb / view.action?id=FP312898), respectively, to find the constant region of heavy chain and constant region of light chain of porcine IgG. In order to improve the expression efficiency of CHO cells, the mouse variable region and the porcine constant region were recombined and codon optimized, and sent to Qingke Biotechnology Co., Ltd. for synthesis. At the same time, the synthesized sequences were constructed into the pcDNA3.4 transient transfection vector, and the inserted restriction sites were XbaⅠ and AgeⅠ for subsequent transient expression. The schematic diagram of the recombination of the variable region and the constant region is shown in the figure. Figure 1 shown.
[0065]
[0066] Nucleotide sequence (SEQ ID NO.2) of the recombinant light chain fragment expressed after codon optimization: GCCACCATGGGTTGGTCTTGTATCATCTTGTTCTTGGTCGCTACCGCAACAGGTGTGCATAGCGACATCGTGTTGACTCAGAGTCCAGCTTCTTTGGCTGTCAGCCTGGGCCAGAGAGCCACCATCTCTTGCCGTGCTTCCAAGAGCGTGTCCATCAGCGGTCATAGCTATATGCACTGGTATCAGCAGAAGCCTGGTCAACCACCTAAGCTGCTGATTTACCTCGCCTCTAACTTGGAGAGCGGCGTGCCAGCTAGGTTTAGCGGCTCTGGCTCCGGCACAGATTTCACCTTGAACATTCATCCAGTGGAAGAAGAAGATGCCGCTACCTACTATTGCCAGCATTCACGGGAATTGCCACCTACCTTTGGCTCAGGCACTAAGTTGGAGATCAAGAGGGCTGATGCCAAGCCAAGCGTGTTCATCTTTCCACCAAGCAAAGAACAGCTGGAGACACAGACCGTGAGCGTGGTCTGTTTGCTGAACAGCTTCTTCCCAAGAGAGGTCAATGTTAAGTGGAAGGTCGATGGTGTGGTGCAGTCTAGTGGCATCTTGGACTCTGTCACCGAGCAAGACTCTAAGGACAGCACCTACAGCCTCAGCTCTACTCTGAGCCTGCCAACTTCTCAGTATCTGTCTCATAACCTGTATTCTTGCGAGGTGACTCACAAGACACTGGCCTCACCTCTGGTGAAGAGCTTCTCACGGAATGAGTGCGAAGCAtga
[0067] 1.2.3 Construction of the chimeric antibody stable transfection vector
[0068] In order to obtain a monoclonal cell line that stably expresses chimeric antibodies, it is necessary to reconstruct a stable vector based on the transient vector, and homologously recombine the amplified heavy chain fragment with the double-enzyme-digested PKS001 vector. After transformation and single identification, double-enzyme digestion of the light chain site is continued, and homologous recombination with the amplified light chain fragment is performed. After transformation and single identification, the construction of the stable vector is completed; the constructed stable plasmid is transferred into CHO-K1 cells, and stable cell lines and monoclonal cell lines are screened to finally obtain a CHO cell line that stably expresses chimeric antibodies. The cell culture supernatant is purified to obtain the final pig-mouse chimeric antibody. The specific experimental process is shown in Figure 2 .
[0069] Porcine CH amino acid sequence of pig-mouse chimeric antibody ch1H10 (SEQ ID NO.3): APKTAPSVYPLAPCGRDTSGPNVALGCLASSYFPEPVTMTWNSGALTSGVHTFPSVLQPSGLYSLSSMVTVPASSLSSKSYTCNVNHPATTTKVDKRVGTKTKPPCPICPGCEVAGPSVFIFPPKPKDTLMISQTPEVTCVVVDVSKEHAEVQFSWYVDGV EVHTAETRPKEEQFNSTYRVVSVLPIQHQDWLKGKEFKCKVNNVDLPAPITRTISKAIGQSREPQVYTLPPPAEELSRSKVTVTCLVIGFYPPDIHVEWKSNGQPEPEGNYRTTPPQQDVDGTFFLYSKLAVDKARWDHGETFECAVMHEALHNHYTQKSISKTQGK
[0070] The amino acid sequence of porcine CL of the porcine-mouse chimeric antibody ch1H10 (SEQ ID NO.4):
[0071] RADAKPSVFIFPPSKEQLETQTVSVVCLLNSFFPREVNVKWKVDGVVQSSGILDSV TEQDSKDSTYSLSSTLSLPTSQYLSHNLYSCEVTHKTLASPLVKSFSRNECEA
[0072] The mouse VH amino acid sequence of the pig-mouse chimeric antibody ch1H10 (SEQ ID NO.5):
[0073] EVKLLESGGGLVQPGGSLKLSCAASGFDLSRYWMSWVRQAPGKGLEWIGEINPDSRTINYTPSLKDKFIISRDNAKNTLNLQMSKVRSEDTALYYCARQGRGFAYWGQGTLVTVSA
[0074] The mouse VL amino acid sequence of the pig-mouse chimeric antibody ch1H10 (SEQ ID NO.6):
[0075] DIVLTQSPASLAVSLGQRATISCRASKSVSISGHSYMHWYQQKPGQPPKLLIYLASN LESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPPTFGSGTKLEIK
[0076] The antibody recombinant heavy and light chain fragments were successfully inserted into the pcDNA3.4 transient transfection vector with restriction sites XbaⅠ / AgeⅠ as the template to amplify the recombinant heavy and light chain fragments. PKS001 has multiple cloning sites, and the recombinant heavy chain fragments were inserted into the XbaⅠ and NotⅠ restriction sites, and the light chain fragments were inserted into the HindⅢ and EcoRⅠ restriction sites. The specific steps are:
[0077] 1) First, the PKS001 vector was double-digested with restriction endonucleases XbaⅠ and NotⅠ at the site where the heavy chain needed to be connected, and then the concentration of the recombinant heavy chain amplified fragment and the purified product of the digested vector was measured, and the two were connected using 2xSeamlessCloning Mix, and reacted at 50℃ for 25 minutes. Finally, the stable vector connection product of the antibody recombinant heavy chain was transferred into TOP10 competent cells,
[0078] After the competent bacterial plate grows colonies, randomly select colonies for identification. Pick a certain number of colonies and use 50μl Amp + The liquid culture medium is resuspended and mixed, and the bacterial solution is used as an amplification template for identification. After sequencing is correct, the bacterial solution is expanded and cultured, and the endotoxin-free plasmid is extracted. The plasmid is then digested with restriction endonucleases HindⅢ / EcoRⅠ, and the digestion products are used for subsequent light chain connection.
[0079] 2) The concentration of the antibody recombinant light chain amplified fragment and the purified product of the double-enzyme digested plasmid were measured, and the two were connected using 2xSeamless Cloning Mix. The antibody light chain stable vector connection product was then transferred into TOP10 competent cells. After colonies grew on the competent bacterial plate, colonies were randomly selected for identification. A certain number of colonies were picked and 50 μl of Amp+ The liquid culture medium was resuspended and mixed, and the bacterial solution was used as an amplification template for identification. After sequencing, the bacterial solution was expanded and cultured to extract the endotoxin-free plasmid, PKS001-ch1H10 plasmid.
[0080] 3) Since the extracted plasmid may be contaminated by bacteria and the concentration is relatively low, the extracted PKS001-ch1H10 plasmid is sterilized, concentrated and recovered by ethanol precipitation. The steps are as follows: add 6μl 3M pH3.5 NaAc solution to the PKS001-ch1H10 plasmid and mix gently; then add 180μl anhydrous ethanol cooled at 4°C and mix gently; centrifuge instantly and gently remove the supernatant; add 1ml 75% ethanol, centrifuge instantly, and gently remove the supernatant, repeat this step for 6 times; remove the 75% ethanol used for washing, blow dry the plasmid in a biological safety cabinet for 10 minutes, add 30μl sterile ddH2O to dissolve it, and finally measure the concentration of the plasmid.
[0081] 1.2.4 Expression and purification of chimeric antibodies
[0082] 1.2.4.1 Transient transfection of chimeric antibodies
[0083] The cells needed for transient transfection are ExpiCHO-S. The cells are taken out of liquid nitrogen for recovery. The cells are also suspended and cultured under the following conditions: 95rpm, 37℃, 8% CO2. The culture medium used is the special culture medium ExpiCHO Expression Medium. After cell recovery, the cells are inoculated at a density of 2*10 5 cells / ml, and then continuously subcultured until 1 day before transfection, at a rate of 3*10 6 cells / ml, and pass them into two shake flasks, 50 ml in each flask, for later use. The plasmid to be used is PKS001-ch1H10 plasmid.
[0084] On the second day, adjust the ExpiCHO-S cells to 6*10 6 cells / ml, 50ml / bottle; take two sterile 15ml centrifuge tubes, mark them A and B respectively, and add the components according to Table 6.
[0085] Table 6 Transient transfection system
[0086]
[0087] After the addition is complete, transfer the liquid in tube B to tube A, slowly drip while rotating the pipette tip, gently mix and let stand at room temperature for 5 minutes; take out the cells to be used, slowly add the mixed liquid into it, and shake the cells at the same time; after the addition is complete, mix the cells, count the cells, and put the cells back into the carbon dioxide shaker for continued cultivation.
[0088] 20 hours after transfection, remove the cells, add 8 ml ExpiCHO Feed and 300 μl ExpiCHO Enhancer to each shake flask, mix well, take a small amount of cells to count, and return the cells to the carbon dioxide shaker for culture at 95 rpm, 37°C, 5% CO2.
[0089] On the 5th day of culture, add 8 ml of ExpiCHO Feed to each shake flask and return it to the carbon dioxide shaker for culture at 95 rpm, 37°C, 5% CO2. Count and observe the cells every day until the cell viability drops below 70%, then collect the cell supernatant for verification.
[0090] 1.2.4.2 Purification and concentration of chimeric antibodies
[0091] The cell supernatant was purified using a Protein A recombinant protein purification pre-packed column. The purification steps are as follows: wash the machine and purification column with distilled water; rinse with binding buffer (20mM phosphate buffer, 150mM NaCl, pH7.4) after numerical equilibrium; filter the cell culture supernatant with a 0.45μm filter membrane after numerical equilibrium, and then load the sample for purification; after all samples are loaded, wash the purification column with binding buffer; after numerical equilibrium, wash the column with elution buffer (0.1M citric acid buffer, pH4.0), collect the eluted liquid, and immediately adjust the pH value to neutral. The chimeric antibody collected by elution was ultrafiltered and concentrated using a 50MWCO ultrafiltration tube, and the antibody concentration was measured.
[0092] 1.2.4.3 Stable transfection of chimeric antibodies
[0093] Take the CHO-K1 cells that are being subcultured, count them, and lay them on a 6-well plate. 6 The living cells were plated and placed in an incubator for shaking culture for later use.
[0094] On the second day after cell plating, prepare for transfection experiment. The transfection steps are as follows: according to the cell volume, absorb the corresponding mass of PKS001-ch1H10 plasmid, and perform it according to the ratio of 1μg plasmid to 1ml cell. First, dilute it with CHO CD04 Medium, and add 100μl culture medium for every 1μg plasmid; after blowing and mixing, add HighGene reagent at a ratio of 3 times the mass of the plasmid, mix and let stand for 10 minutes; add the mixed liquid to the 6-well plate cells prepared in advance; put the cells into the incubator and continue to shake and culture. After transfection for 3-5 days, take the stable transfected cells to culture and express chimeric antibodies. You can also take the stable transfected cells and perform monoclonal cell screening after pressure screening to obtain high-expressing monoclonal cells for seeding.
[0095] 1.2.5 In vitro activity characterization of chimeric antibodies
[0096] 1.2.5.1 SDS-PAGE identification of ch1H10
[0097] The protein loading buffer used in non-reducing SDS-PAGE does not contain mercaptoethanol, which can retain the disulfide bonds between antibodies and keep the antibody's molecular structure intact, and is used for the identification of complete multimeric proteins / antibodies; the protein loading buffer used in reducing SDS-PAGE contains mercaptoethanol, which is used to observe the monomer size of the antibody's heavy chain and light chain. The specific steps are as follows:
[0098] (1) Non-reducing SDS-PAGE:
[0099] Add 10 μl 5x non-reducing protein loading buffer to 40 μl of the antibody to be tested at an appropriate concentration; react the mixture at 90°C for 1 min and cool it; add the sample and marker to a 7.5% electrophoresis gel and perform vertical gel electrophoresis at 80V, 25min; 120V, 60min; after electrophoresis, use Coomassie Brilliant Blue for staining and decolorization; take images and record them.
[0100] (2) Reducing SDS-PAGE:
[0101] Add 10 μl of 5x reducing protein loading buffer to 40 μl of the antibody to be tested; react the mixture in a water bath at 100°C for 5 min and wait for the sample to cool completely; the remaining steps are the same as "non-reducing SDS-PAGE".
[0102] 1.2.5.2 Cytotoxicity assay of ch1H10
[0103] The ch1H10 used in this experiment was obtained by transient transfection, with a concentration of 1.285 mg / ml. ST cells were laid on a 96-well plate and grown for about 24 hours; 10 μl of chimeric antibodies of different concentrations were added to the 96-well plate, and 3 replicate wells were set for each concentration; after 48 hours of co-incubation, 10 μl of CCK-8 solution was added to each well and incubated for another 2 hours; OD was measured using an enzyme reader 450nm Read the value.
[0104] The cytotoxicity of the chimeric antibody was calculated according to the formula cell viability (%) = [A (drug added) - A (blank)] / [A (0 drug added) - A (blank)] × 100, where A (drug added) refers to the OD value of the wells with cells, CCK-8 and antibodies, A (blank) refers to the OD value of the wells with only culture medium and CCK-8 but no cells, and A (0 drug added) refers to the OD value of the wells with only cells and CCK-8 but no antibodies. Whether the antibody is cytotoxic is determined based on the calculated cell viability.
[0105] 1.2.5.3 EC50 determination of ch1H10
[0106] The antibody concentration used in this experiment is the same as that in 1.2.5.2. When the ST cells are nearly full (80% to 90%), prepare for virus incubation; according to the virus TCID previously determined in the laboratory, 50 Data, the 107th generation PDCoV virus was diluted 330,000 times (serum-free DMEM was used as the diluent); at the same time, the chimeric antibody was processed and gradiently diluted according to the experimental requirements (serum-free DMEM was used as the diluent). Finally, the diluted virus solution was added to the antibody diluent at a ratio of 1:1, and the mixture was placed in a 37°C incubator for reaction for 1 hour; the virus-antibody mixture after the reaction was added to the pre-cultured ST cells, 100 μl per well, 6 replicates for each experimental group, and the cells were continued to be cultured, and the cell pathology was observed daily. When the cells showed obvious pathology, the pathology data of the cell wells in each experimental group were recorded. When exactly half of the cell wells (3) in the experimental group showed pathology, the antibody concentration under this condition was EC 50 .
[0107] 1.2.5.4 Analysis of the binding ability of ch1H10 to viral S1 protein
[0108] This experiment uses the PDCoV S1 fragment protein available in the laboratory, and the antibody concentration used is the same as 1.2.5.2. Coating: dilute the protein with the coating solution and add it to the ELISA plate, 1μg per well, volume 100μl. Incubate at 37℃ for 1h and then incubate at 4℃ overnight; Wash the plate: Pour off the protein coating solution and pat dry, add 250μl PBST to each well for shaking washing, a total of three times, 3min each time. Pat the plate dry after the last wash; Blocking: At room temperature, use self-prepared 5% skim milk powder to block the ELISA plate, 100μl / well, incubate at 37℃ for 1.5h; Washing: Same as the above washing steps; Primary antibody incubation: According to experimental requirements, add chimeric antibody solution with different dilution ratios, 100μl / well, set up 3 replicates, and incubate at 37℃ for 1h; Wash the plate three times; Secondary antibody incubation: Use HRP-goat anti-pig IgG for the experiment, dilute the secondary antibody 4000 times, 100μl / well, incubate at 37℃ for 0.5h or at room temperature for 1h; Wash the plate three times; Color development and termination: Add color development solution, 100μl / well, room temperature away from light for 15min, and then add 100μl of commercial H2SO4 stop solution to each well to terminate; Reading: Use an ELISA plate reader to read OD 450nm The reading value.
[0109] 1.2.5.5 Indirect immunofluorescence experiment of ch1H10
[0110] The antibody concentration used in this experiment is the same as 1.2.5.2. ST cells were plated on a cell slide in a 24-well plate. When the cells grew to 90%, PDCoV was infected at MOI = 0.01; fixation: when the cells just began to show pathological changes, the virus liquid culture medium was discarded, 4% paraformaldehyde was added, and incubated at room temperature for 30 minutes; permeabilization: after fixation, the PBS solution was washed 3 times and the water was discarded. Add an appropriate amount of 0.1% Triton X-100 to cover the cells, incubate at room temperature for 30 minutes and wash again 3 times; blocking: prepare a 2% BSA-PBS mixture, add it to the 24-well plate to cover the cells for blocking, and block at room temperature for 1 hour; primary antibody incubation: after blocking, there is no need to wash the plate, and the appropriately diluted chimeric antibody or original mouse antibody is used as the primary antibody, 150μl per well, and an equal amount of PBS solution is added to the blank control well. The incubation time is 37℃ for 1h or 4℃ overnight; secondary antibody incubation: after the primary antibody incubation is completed, use PBST for shaking and washing, 3min / time, for a total of 3 times. The experimental wells of the chimeric antibody and the blank control use FITC-goat anti-pig IgG as the secondary antibody, and the original antibody experimental wells use 555-donkey anti-mouse IgG as the secondary antibody. Incubate at 37℃ in the dark for 1h; nuclear staining and result observation: after the secondary antibody incubation is completed, wash with PBST for 3 times, pour off the liquid, take out the slide and turn it upside down in the anti-fluorescence attenuation mounting medium (containing DAPI), and finally use a fluorescence microscope to observe the results and save the pictures.
[0111] 1.2.6 In vivo animal treatment experiments with ch1H10
[0112] The schematic diagram of the whole treatment experiment is shown in Figure 3 The antibody concentration used was the same as in 1.2.5.2. One day after stress was eliminated, the piglets were challenged orally, and 12 hours later, the antibody was injected intramuscularly. The mental state and feces of the piglets were recorded daily after the challenge, and the situation near the anus of the piglets was photographed and recorded. Six days after the challenge, all the piglets in the experimental groups were uniformly autopsied.
[0113] 1.2.6.1 Animal grouping and challenge
[0114] Thirteen healthy 5-day-old piglets were prepared and randomly divided into three groups: 5 piglets in the virus control group, 5 piglets in the antibody treatment group, and 3 piglets in the blank control group. Pre-feed for 1 day to eliminate stress, collect anal swabs from all piglets when they are healthy, add 1 ml of sterile PBS to the swabs, and store them in a -80°C refrigerator. Use crystal violet solution to mark the backs of the piglets for distinction. The piglets in the antibody treatment group are numbered ZL1~ZL5, the virus control group are numbered GD1~GD5, and the blank control group are numbered MOCK1~MOCK3. The three groups of piglets were fed in separate rooms. The specific grouping is shown in Table 7. After 1 day of pre-feeding, the 21st generation PDCoV virus available in the laboratory was used for virus attack. The TCID of the virus of this generation 50 About 10 5.7 / 100μl, and the piglets were orally challenged with the drug according to the data. The challenge dose for the control group and the antibody treatment group was 10 7 TCID 50 / mL, and the blank control group received the same dose of DMEM medium. The specific doses are shown in Table 7.
[0115] Table 7 Grouping of piglets in the experiment
[0116]
[0117] 1.2.6.2 Injection of chimeric antibodies
[0118] 12 hours after the challenge, the body weight of the piglets in the antibody treatment group was measured, and ch1H10 (1 mg / kg) was injected intramuscularly according to the body weight. At the same time, the piglets in the challenge control group and the blank control group were injected intramuscularly with an equal amount of DMEM (1 mg / kg).
[0119] 1.2.6.3 Clinical observation records
[0120] After the infection, the mental state of the piglets was recorded every 8 hours to observe whether the piglets showed symptoms such as depression and decreased appetite. The feces of the piglets were recorded, and the diarrhea score of the piglets was calculated according to the diarrhea table (see Table 8) to analyze the severity of diarrhea in the piglets during the experiment.
[0121] Table 8 Stool score table
[0122]
[0123] 1.2.6.4 Dynamic detoxification monitoring
[0124] After the virus attack, the piglet anus swab was collected once a day, and 1 ml of sterile PBS was added to the swab and stored in a -80°C refrigerator for later analysis of the changes in the piglet's excretion of toxins. While collecting the swab, the piglet's anus was photographed and recorded to facilitate the analysis of changes around the anus caused by diarrhea in the piglet.
[0125] 1.2.6.5 Observation of lesions after autopsy and submission for examination
[0126] On the 6th day after the virus attack, the piglets were anesthetized and dissected, and the intestinal conditions of each piglet were recorded. The main observation was whether the piglet's intestines were congested, thinned, transparent, etc.; and the morphology of the intestinal contents was observed. The small intestine segments (duodenum, jejunum, ileum) and large intestine segments (cecum, colon, rectum) of each piglet were collected in turn. The specific operation was: use sterile surgical scissors to cut about 1 cm of the intestine and place it in 4% paraformaldehyde solution; then cut the intestine segments of equal length, place them in 2mL centrifuge tubes and store them in a -80℃ refrigerator for later use. The fixed jejunal and ileal tissues were sent to Bios Biotechnology Co., Ltd. for HE staining and immunohistochemical analysis. The antibody used in the immunohistochemical experiment was the mouse monoclonal antibody 1H10 made in this laboratory, and the target was the PDCoV S protein, and the antibody dilution multiple was 1:600.
[0127] 1.2.6.6 Determination of enteric viral load
[0128] Use a centrifuge tube with small steel balls, weigh 30 mg of intestinal tissue and put it into the centrifuge tube, and use a grinder to crush and grind it. Add 400 μl Trizol lysis solution to the crushed tissue, put it in a -80℃ refrigerator for one freeze-thaw cycle, and then use the frozen and thawed liquid to extract RNA. The extraction steps are carried out according to the instructions of the SteadyPure RNA extraction kit of Acori Biotechnology. After the extraction, reverse transcription of RNA is performed immediately.
[0129] RNA extraction from anal swabs does not require the use of Trizol lysis buffer. First, thoroughly mix the liquid in each tube of anal swabs and draw an equal amount of 100 μl suspension. The subsequent extraction steps are carried out according to the instructions of the SteadyPure Rapid RNA Extraction Kit of Acori Biotechnology, and the extracted RNA is also immediately reverse transcribed.
[0130] 1.2.6.7 Reverse transcription and fluorescence quantitative PCR
[0131] According to the instructions of HiScript IIQ RT SuperMix for qPCR (+gDNAwiper) kit of Novozymes, the RNA extracted in the previous step was reverse transcribed.
[0132] Fluorescence quantitative PCR was used to determine the content of PDCoV in the intestinal tissue and anal swabs of piglets. The detection primers used were PDCoV NF: CTATGAGCCACCCACCAA, PDCoV NR: TCCCACTCCCAATCCTGT. PDCoVN plasmid was also used for the experiment at a concentration of 740 ng / μl, and the dilution was repeated to take 10 -3 ~10 -10 The 8 concentration gradients were used for the experiment, and the standard curve was run for absolute quantification. The experiment was carried out according to the instructions. The total reaction system was 15 μl, including 7.5 μl of 2×ChamQUniversal SYBR qPCR Master Mix, 0.3 μl of upstream and downstream primers, 1.5 μl of cDNA template, and 5.4 μl of ddH2O. Reaction conditions: 95℃30s; 95℃10s, 60℃30s, 39 cycles; 65℃5s, 95℃5s.
[0133] 2. Research Results
[0134] 2.1 Codon optimization and transient vector synthesis
[0135] After codon optimization and synthesis by Qingke, the recombinant antibody fragment was successfully constructed into the transient vector pcDNA3.4. The schematic diagrams of the two transient vectors are shown in Figure 4 , the antibody heavy and light chain fragments were inserted into the restriction site XbaⅠ / AgeⅠ.
[0136] 2.2 Construction of stable transfection vector of chimeric antibody 1H10
[0137] The heavy chain fragment of antibody 1H10 was successfully amplified using primers 1H10-HF (sequence: TCTAGAGCCACCATGGGCTGGTCT) and 1H10-HR (sequence: GCGGCCGCTCACTTGCCCTGTGTCTTGGA), with a length of 1398 bp; the results are shown in Figure 5. The amplified fragment was homologously recombined with the PKS001 vector that had been double-digested with XbaⅠ and NotⅠ, and the PKS001-1H10-H vector was successfully constructed. After sequencing by Sangon, the light chain was amplified using primers 1H10-LF / 1H10-LR (sequence: AAGCTTGCCACCATGGGTTGGTCTT / GAATTCTCATGCTTCGCACTCATTCCG), and the length of the antibody 1H10 light chain fragment was 726bp. At the same time, the constructed heavy chain plasmid was double-digested with HindⅢ and EcoRⅠ. After homologous recombination and transformation of the light chain fragment and the heavy chain plasmid, the PKS001 stable vector carrying the heavy and light chain fragments was successfully obtained. The size of the PKS001-ch1H10 plasmid is 11480bp. See the schematic diagram of the plasmid for details. Figure 6 .
[0138] 2.4 Expression and purification of chimeric antibodies
[0139] 2.4.1 Transient transfection
[0140] After transient transfection of EXPI-CHOS cells, the cells were cultured and expressed normally, but due to limited conditions, they could not be cultured at 32°C, resulting in the cell activity dropping below 70% on the 10th day. The supernatant of the transiently transfected cells was collected by centrifugation 10 days after transfection and subsequent purification was carried out.
[0141] 2.4.2 Purification and concentration of chimeric antibodies
[0142] The CHO-K1 cell culture supernatant was purified using a recombinant protein A purification column, and the elution peak was collected and pH neutralized. The peak diagram of the purification process is shown in FIG. Figure 7 As shown. The antibody concentration after purification is low and needs to be concentrated. The antibody eluate is ultrafiltered and concentrated using a 50000MWCO ultrafiltration tube to obtain 8 ml of ch1H10 with a concentration of 1.285 mg / ml.
[0143] 2.4.3 Stable transfection
[0144] The constructed stable transfection plasmid PKS001-ch1H10 was transfected into the 6-well plate CHO-K1 cells prepared in advance. 4 days after transfection, the cells were transferred to T75 cell culture flasks for subsequent screening.
[0145] 2.4.4 Establishment of monoclonal cell line of ch1H10
[0146] After about two weeks of pressure screening, the CHO-K1 cells transfected with ch1H10 had recovered their growth activity, and the monoclonal cell line was established. After expansion culture, a total of 44 effective clones were obtained. The clone supernatant was verified using an ELISA plate coated with PDCoV S protein. The order of supernatant loading is shown in Table 9. According to the final OD 450nm The readings were calculated and 16 clones with relatively high readings were selected for expansion culture and finally for seed preservation. The reading results are shown in Table 10.
[0147] Table 9 Supernatant addition order
[0148]
[0149] Table 10 Supernatant ELISA verification reading results
[0150]
[0151] 2.5 Identification of in vitro activity of ch1H10
[0152] 2.5.1 SDS-PAGE identification of ch1H10
[0153] SDS-PAGE was performed on the ch1H10 cell culture supernatant, purified flow-through, and purified antibodies. The results showed that under non-reducing conditions, the size of ch1H10 was about 150KDa. In the cell supernatant, relatively concentrated antibody heavy chain bands (about 50KDa) and light chain bands (about 23KDa) were visible; in the flow-through, the heavy chain and light chain bands were significantly lighter. The results showed that the ch1H10 antibody was successfully expressed and purified, and the correct assembly (heavy chain + light chain) also occurred. In the lane of the purified sample, in addition to the normal complete antibody bands, there were two particularly shallow antibody heavy chain and light chain bands. It is speculated that a small amount of antibody disulfide bonds were broken during the sample processing, resulting in the splitting into separate heavy chains and light chains. For details, see Figure 8 (A) The purified antibody samples were then separately verified by reducing / non-reducing SDS-PAGE. Figure 8 As shown in (B), the purified and concentrated ch1H10 can be separated into heavy chain and light chain under reducing conditions, and the structure is correct.
[0154] 2.5.2 Cytotoxicity test of ch1H10
[0155] According to the neutralization effect of the original mouse 1H10, 24μg / ml, 12μg / ml, 6μg / ml, 3μg / ml and 1.5μg / ml antibody concentrations were selected for cytotoxicity experiments. After adding the antibody, the cells were placed in an incubator and cultured for 48 hours to simulate the long-term presence of chimeric antibodies in animals. After adding CCK-8 reagent, the cells were cultured for 2 hours and the results were analyzed after color development. Fig. 9 It can be seen that the cell activity of ST cells incubated with various concentrations of ch1H10 was higher than 100% after 48 hours, and there was no obvious dose-dependent trend, indicating that ch1H10 had no cytotoxicity to porcine cells.
[0156] 2.5.3 Determination of EC50 value of ch1H10
[0157] According to the concentration of purified and concentrated ch1H10, the antibody was diluted at a ratio of 1:50, 1:75, 1:100, 1:150, 1:200, 1:300, 1:400, 1:600, 1:800, and 1:1200. According to the existing virus titer data in the laboratory, the 107th generation PDCoV was diluted 330,000 times, and the diluted virus solution was mixed with the antibody diluent at a ratio of 1:1. According to the experimental process described previously, the cell lesions were observed and the data were sorted. The results are as follows Fig.10 As shown in Figure 2, when the dilution ratio was 1:200-1:300, about half of the cell wells had obvious pathological changes, indicating that the EC of ch1H10 50 In this dilution ratio range, the antibody concentration is about 3.125-4.16 μg / ml.
[0158] 2.5.4 ELISA binding ability analysis of ch1H10
[0159] PDCoV S1 protein was used to coat the ELISA plate. According to the ELISA experimental process, the dilution ratios of antibody ch1H10 were 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, and 1:25600. The experimental results showed that when ch1H10 was diluted 1:6400, it could still bind well to PDCoV S1 protein. The antibody concentration at this time was about 0.2μg / ml, and the OD 450nm The reading is about 0.59. Fig.11 Specific OD value data are shown in Table 11.
[0160] Table 11 ELISA experimental specific data
[0161]
[0162] 2.5.5 Identification of ch1H10 by indirect immunofluorescence assay
[0163] According to the laboratory's previous virus research, a 330,000-fold diluted 107th generation PDCoV was inoculated into a 24-well cell slide of ST cells, and subsequent experiments could be carried out after incubation at 37°C for 24 hours. After fixation, permeabilization, blocking and other steps, ch1H10 with a final concentration of 10μg / ml was used for overnight incubation. At the same time, the same concentration of the original mouse 1H10 antibody was set as the control group, and a blank control group of PBS solution was set. In terms of secondary antibodies, the experimental wells and blank control groups of antibody ch1H10 used a 200-fold diluted FITC goat anti-pig fluorescent secondary antibody, while the mouse antibody control wells used a 200-fold diluted 555-donkey anti-mouse fluorescent secondary antibody. The operation of all experimental wells was kept consistent, and finally the cell slides were deducted and nuclear staining and fixation were performed. Under fluorescence microscopy, obvious fluorescence could be observed in the cell slides of the experimental wells and the mouse anti-control wells. The fluorescence location was all in the cytoplasm, and the fluorescence intensity was equivalent to the quantity; there was no fluorescence reaction in the blank control wells. This result shows that ch1H10 can bind to the live PDCoV virus. For details, see Fig.12 (40x objective field of view), Fig.13 (100x objective field of view).
[0164] 2.5.6 In vivo challenge and treatment experiment of ch1H10 in piglets
[0165] One day before the challenge, the piglets were fed normally and ensured to be healthy. After 24 hours of eliminating the stress caused by the transportation of the piglets, the oral challenge was carried out, and the feces and mental state of the piglets were recorded as planned. 12 hours after the challenge, the piglets were weighed and the injection amount of antibodies was arranged according to the weight. The specific weight data and antibody injection amount are shown in Table 12.
[0166] Table 12 Body weight and antibody injection amount in treatment groups
[0167]
[0168] 2.5.6.1 Analysis of piglet mental state and feces
[0169] During the attack, all piglets showed no abnormalities, were in good spirits and ate normally.
[0170] The challenge control group: 0-12h after the challenge, the piglets had no obvious abnormalities and no diarrhea symptoms; starting from the 16th hour after the challenge, the piglets' appetite decreased, only 50% of the normal state, and there was no obvious change in the feces state at this time; from 24h to 32h, the piglets in the challenge group still had a poor appetite, and at the most serious time, the food intake was only about 30% of the healthy state, the spirit was sluggish, and they often stood still. The piglets in this stage had severe watery diarrhea; starting from the 40th hour, the piglets' appetite began to improve, but the amount of feces outside the cage decreased. When collecting anal swabs, feces splashed as the swab entered; until the 72nd hour, most piglets had a significantly improved mental state and their diarrhea was relieved, but GD-1 and GD-5 still had watery diarrhea, and watery feces overflowed when collecting anal swabs. At the 80th hour, piglet GD-1 became depressed, had cold hands and feet a few hours later, and died soon after; piglet GD-5 also had similar symptoms at the 96th hour and died at the 100th hour. In the following period, the remaining three piglets were in good condition, their feces gradually hardened, and they were killed on the 6th day after the infection.
[0171] Antibody treatment group: 0-12h after the challenge, the piglets also had no obvious abnormalities and no diarrhea symptoms; 16h after the challenge and 4h after the antibody treatment, the piglets also showed symptoms of decreased appetite, but the situation was better than that of the challenge control group, and the food intake was only reduced by about 30% compared with the healthy period. At this time, the mental state and feces of most piglets were normal, and only piglet ZL-3 had diarrhea and was listless; 24-72h after the challenge and 12-60h after the antibody treatment, the piglets all had watery diarrhea and large feces. However, the mental state was much more normal than that of the challenge control group, with no sluggish standing. The piglet was excited and scrambled for food during feeding. During this period, the ZL-3 piglet was relatively depressed and had relatively severe diarrhea. After that, the diarrhea of the piglets in the treatment group improved, the feces began to dry and harden, and the ZL-3 piglet gradually returned to normal. About 108 hours after the challenge, the ZL-5 piglet was observed to have diarrhea, but the situation was not serious, and the feces returned to normal about 32 hours later. It was speculated that it might be secondary infection or diarrhea caused by freezing at night. All piglets were killed on the 6th day after the challenge.
[0172] Blank control group: The three piglets in this group showed no abnormal changes during the experiment, had a normal diet, were in good mental state, and had no obvious diarrhea symptoms.
[0173] The detailed fecal scores of piglets during the experiment are shown in Fig.14 As shown, the anus of the piglet is shown in Fig.15 , 16 , 17, of which Fig.16Due to a shooting error, the 2d picture of the ZL5 piglet in the treatment group was missing, so there are only 4 groups of pictures. The longer the diarrhea lasts and the more severe the diarrhea is, the more feces will remain around the anus and the dirtier the appearance will be. When the diarrhea improves, the hygiene around the anus will also improve.
[0174] In summary, the results showed that the diarrhea symptoms of piglets in the antibody treatment group were milder than those in the virus-challenged control group, and they recovered faster.
[0175] 2.5.6.2 Piglet autopsy
[0176] Except for GD-1 and GD-5 which died of disease, the remaining piglets were autopsied on the 6th day after infection.
[0177] There were no obvious abnormalities in the autopsy of the three piglets in the blank control group. Due to insufficient bleeding, the intestinal tract of the MOCK-3 piglet was congested, but the mesenteric lymph nodes were not congested. For details, see Fig.18 .
[0178] The pathological changes of the GD-1 and GD-5 piglets that died of the disease were obvious, with obvious congestion in the intestines and mesenteric lymph nodes, thinning and transparent intestinal walls, and obvious liquid and gas inside (black arrows). When separating the samples, it can be clearly felt that the intestinal tissue is in a fragile and easily broken state.
[0179] Except for GD-1 and GD-5, the other three piglets in the challenge control group did not have severe intestinal congestion. The intestinal wall of the jejunum of GD-2 and GD-3 piglets was thinned, with obvious fluid (black arrows), but the large intestine was normal, and relatively moist feces were seen at the end of the rectum. The intestinal tissue of the GD-4 piglet was normal, without obvious thinning or flatulence, and even relatively formed yellow feces (red arrows) were seen. For details, see Fig.19 .
[0180] No obvious characteristic pathological changes were found in the autopsy of the five piglets in the antibody treatment group. The intestine of piglet ZL-1 was firm (yellow arrow) without obvious symptoms such as flatulence and thinning. Formed dry feces (red arrow) were even seen in the colon of piglet ZL-2. The jejunum of piglet ZL-4 had slight transparent thinning symptoms (black arrow). The rest had no obvious abnormalities. For details, see Fig. 20 .
[0181] In summary, the results showed that ch1H10 had a certain protective effect on piglets, and the degree of intestinal lesions was mild, which was significantly improved compared with the challenge group.
[0182] 2.5.6.3 Determination of viral load in the intestine of piglets
[0183] RNA was extracted from the intestinal samples, and then reverse transcribed and tested by fluorescence quantitative PCR. The results showed that PDCoV could be detected in all intestines. In the duodenum, except for GD2 and GD4, the viral loads of the other challenged piglets were significantly higher than those of the treatment group. In the jejunum and ileum, the viral loads of the challenged piglets were significantly higher than those of the treatment group, with significant differences. In the large intestine (colon, cecum, and rectum), the difference was even more significant. The intestinal viral loads of GD2 and GD4 piglets were always low, and were at a similar level to some piglets in the treatment group. On the contrary, the intestinal viral loads of the dead piglets GD1 and GD5 were always at the highest level, reaching or even exceeding 10 8 Copies / mL; the level of enterovirus in ZL1 piglets in the treatment group was the highest in the same group, with only a slight difference from the challenge group; Overall, the number of viral copies in the intestinal tissue of piglets in the antibody treatment group was significantly lower than that in the virus control group. The detailed viral copy numbers of the intestinal tissues of the three groups of piglets are shown in Fig.21 .
[0184] In summary, the results showed that ch1H10 can effectively neutralize PDCoV, making the overall intestinal tissue virus copy number of the antibody treatment group significantly lower than that of the virus-challenged control group.
[0185] 2.5.6.4 Viral load determination of anal swabs
[0186] The results of fluorescent quantitative PCR test on piglet anal swabs showed that the virus could be detected in anal swabs before autopsy. The piglets in both experimental groups reached the highest excretion of virus 2 to 3 days after infection, and the number of virus copies was 10 7 Copies / mL to 10 9 Copies / mL, but the subsequent treatment group excretion decreased rapidly, while the challenge group still had a high excretion of toxins at 5 dpi (about 10 7 Copies / mL). For details, see Fig. 22 .
[0187] The results showed that ch1H10 could reduce the amount of toxins excreted by sick piglets in advance and help them recover.
[0188] 2.5.6.5 HE staining analysis of piglet jejunum / ileum
[0189] After autopsy of the experimental piglets, the tissues of the jejunum and ileum were taken to make pathological sections and HE staining was performed. The HE staining results are shown in Fig.23 , Fig.24 , Fig.25. The slice samples of the blank control group were normal in morphology, thick overall, and the intestinal villi were intact; the intestinal samples of the antibody treatment group were generally good, and the intestine did not show thinning. Under the microscope, the intestinal mucosa was normal in morphology, the intestinal villi were neatly arranged, the intestinal glands were regular in shape, and there were few lymphoid follicles in the lamina propria, with only a few chronic inflammatory cells infiltrating. In the intestines of the two piglets ZL-4 and ZL-5, mild edema of the intestinal mucosa and lymphoid follicles were observed. The pathological changes of the samples of the attack control group were more serious, especially the samples of the two dead piglets GD1 and GD5. The jejunum and ileum of the GD1 piglet had extensive necrosis, mucosal epithelial shedding, and obvious intestinal wall thinning and even rupture. It is speculated that the reason may be that the intestine is too fragile and damaged during sampling; a large number of inflammatory cells infiltrated the intestinal lamina propria, and vascular congestion and dilation appeared in many tissues; the samples of the other three piglets were relatively intact, but the intestinal villi also had slight atrophy and shedding.
[0190] The results showed that ch1H10 can effectively protect small intestinal tissue and reduce the damage of PDCoV to intestinal cells.
[0191] 2.5.6.6 Immunohistochemical analysis of piglet jejunum / ileum
[0192] Immunohistochemical analysis of the jejunum and ileum was performed using the original mouse anti-1H10. Positive reactions appeared as brown granules. For details, see Fig.26 , 27 And 28. Except for the blank control group, virus particles can be observed in the jejunum and ileum tissues of piglets in all experimental groups. In the attack control group, GD-1 and GD-5 had the largest number of virus particles, and a large number of brown particles could be clearly seen in the field of vision, and there were a large number of inflammatory cells. Different numbers of virus particles could be detected in the intestinal villi of the other piglets; there were a small number of virus particles in the samples of the antibody treatment group, among which the number of virus particles in ZL-5 was significantly higher than that of the other piglets in the same group. However, except for GD-1 and GD-5, there was no significant difference in the number of virus particles in the piglet samples of the two experimental groups.
[0193] The results showed that ch1H10 could neutralize and reduce the number of viral particles in the jejunum and ileum of piglets to a certain extent.
[0194] 3. Conclusion
[0195] This study successfully constructed a recombinant vector for expressing pig-mouse chimeric antibodies through genetic engineering recombination technology, and expressed the chimeric antibody ch1H10 in CHO cells. Cell experiments have shown that the recombinant antibody has good virus binding activity and neutralization activity. In vivo experiments have shown that the chimeric antibody has an antiviral therapeutic effect on PDCoV-infected piglets, providing a strain for the prevention and treatment of PDCoV that can avoid heterologous reactions and has good antibody neutralization therapeutic effects. It is a practical genetic engineering antibody with important clinical application value.
Claims
1. A pig-mouse chimeric antibody against porcine delta coronavirus, Features: It is composed of a heavy chain and a light chain; the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.3, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.5, the amino acid sequence of the light chain constant region is shown in SEQ ID NO.4, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.
6.
2. A gene fragment encoding the pig-mouse chimeric antibody according to claim 1, Features: It includes a gene fragment encoding a heavy chain whose nucleotide sequence is shown as SEQ ID NO.1, and a gene fragment encoding a light chain whose nucleotide sequence is shown as SEQ ID NO.
2.
3. A recombinant vector expressing the pig-mouse chimeric antibody according to claim 1, Features: The expression vector is an expression vector in which a gene fragment encoding a heavy chain as shown in SEQ ID NO.1 is inserted into the XbaⅠ and NotⅠ restriction sites, and a gene fragment encoding a light chain as shown in SEQ ID NO.2 is inserted into the HindⅢ and EcoRI restriction sites; The expression vector includes a PKS001 plasmid vector.
4. A recombinant cell expressing the pig-mouse chimeric antibody according to claim 1, Its features are: It is a mammalian cell comprising the recombinant vector of claim 4, preferably ExpiCHO-S or CHO-K1 cell.
5. A method for preparing the pig-mouse chimeric antibody according to claim 1, Features: The steps include: Take the recombinant vector described in claim 3, transfect cells, culture, and purify the supernatant to obtain; The transfection includes transient transfection and stable transfection.
6. The method according to claim 5, Features: The transient transfection method is as follows: OptiPRO SFM and a recombinant vector are mixed in tube A; OptiPRO SFM and ExpiFectamineCHO Reagent are mixed in tube B; the solutions in tubes A and B are mixed and allowed to stand for 5 minutes, then added to a cell culture medium, and after culturing for 20 hours, ExpiCHO Feed and ExpiCHO Enhancer are added, and culture is continued until the fifth day, and then ExpiCHO Feed is added and cultured until the cell viability drops below 70%.
7. The method according to claim 6, Features: The ratio of OptiPRO SFM to recombinant vector in tube A is 2 ml: 40 μg; The ratio of OptiPRO SFM and ExpiFectamine CHO Reagent in tube B is 1.84 ml:160 μl; the ratio of cell culture medium and recombinant vector is 50 ml:40 μg; The volume ratio of the cell culture medium to the ExpiCHO Feed and ExpiCHO Enhancer added after 20 hours of culture and the ExpiCHO Feed added on the 5th day of culture is 50 ml: 8 ml: 300 μl: 8 ml; The cells in the cell culture medium are ExpiCHO-S cells, and the culture medium is ExpiCHO Expression Medium; The culture conditions are: rotation speed 95 rpm, temperature 37°C, CO 2 Concentration 8%.
8. The method according to claim 5, Features: The stable transfection method is as follows: dilute the recombinant vector with CHO CD04 Medium, add HighGene reagent and let stand for 10 minutes, and transfect CHO-K1 cells with the obtained mixed liquid for 3-5 days; the ratio of the recombinant vector, CHO CD04 Medium and HighGene reagent is 1 μg: 100 μl: 3 μg. The culture conditions are: rotation speed 95 rpm, temperature 37°C, CO 2 Concentration 8%; The purification is to purify the supernatant using a Protein A recombinant protein purification prepacked column.
9. Use of the pig-mouse chimeric antibody according to claim 1 in the preparation of a medicament for preventing and / or treating porcine delta coronavirus infection.
10. A vaccine for preventing porcine delta coronavirus, Features: The vaccine is prepared by taking the pig-mouse chimeric antibody as claimed in claim 1 as antigen and adding a pharmaceutically acceptable carrier.
Citation Information
Patent Citations
Porcine delta coronavirus antibody, kit containing porcine delta coronavirus antibody and application
CN114057868A
Neutralizing monoclonal antibody aiming at conformational epitope of S1 protein of porcine delta coronavirus
CN116253798A
Neutralizing epitope of S1 protein of porcine delta coronavirus and application of neutralizing epitope
CN116925194A
Neutralizing monoclonal antibody for porcine delta coronavirus and application of neutralizing monoclonal antibody
CN118852420A
Porcine coronavirus vaccines
US20200038504A1
Cited By
PRRSV (porcine reproductive and respiratory syndrome virus) mouse-pig chimeric IgM antibody and application thereof
CN121159677A
